Heterogeneity of synthetic factor Xa inhibitors.

@article{Gerotziafas2005HeterogeneityOS,
  title={Heterogeneity of synthetic factor Xa inhibitors.},
  author={Grigoris T. Gerotziafas and Meyer Michel Samama},
  journal={Current pharmaceutical design},
  year={2005},
  volume={11 30},
  pages={
          3855-76
        }
}
Heparins and vitamin K antagonists are the landmarks of antithrombotic treatment. Both of them were discovered by serendipity; they are multi-targeted drugs and share several limitations. New molecules have been designed in order to be both more selective concerning their biological target and more homogeneous in their biochemical structure aiming at an improved benefit/risk ratio in the treatment of thrombotic disease. In this article, we will review the pharmacological characteristics of the… Expand
Factor VIIa and Factor IXa Inhibitors as Anticoagulants: A Review
TLDR
Despite the fact that more complexity is observed in designing of anticoagulant as FVIIa/TF complex and FIXa inhibitors, these will remain an important and validated target for the design and development of antICOagulants. Expand
Newer anticoagulants in 2009
TLDR
Several newer anticoagulants are under clinical development and may be used in a broader variety of patients, especially the medically ill patients with advanced cancer, and the elderly without any dosage adjustment, regardless of the patient age, gender, body weight, or in patients with mild renal impairment. Expand
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
TLDR
The history of rivaroxaban's development is presented, from the structure–activity relationship studies that led to its discovery to the preclinical and clinical studies, and a brief overview of other oral anticoagulants in advanced clinical development is provided. Expand
[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
TLDR
The new anticoagulants are associated with a bleeding risk comparable to that of VKA and heparins and may interfere in routine coagulation tests such as PT or aPTT, and in esoteric assays such as anti-Xa activity. Expand
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
TLDR
The analysis of the available data presented in this review reinforces the request for the design of new Phase III clinical trials for the assessment of the efficacy and safety of NOACs in specific populations of patients with cancer. Expand
Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?
TLDR
The thrombin activity profile performed with the Calibrated Automated Thrombogram((R)) (CAT) method is a very rapid, suitable and reliable pharmacological tool for screeningThrombin and/or FXa inhibitors whatever their inhibition mode. Expand
Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
TLDR
43 novel compounds were synthesized anthranilamide-basedFXa inhibitors aiming to ameliorate the toxicity of traditional FXa inhibitors in clinic and showed remarkable FXa inhibitory activity and excellent selectivity over thrombin in vitro. Expand
Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
TLDR
A series of novel anthranilamide-based FXa inhibitors were designed and synthesized and displayed evident FXa inhibitory activity and excellent selectivity over thrombin in in vitro inhibition activities studies. Expand
Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism
  • W. Wade, W. Spruill
  • Medicine
  • Expert review of pharmacoeconomics & outcomes research
  • 2007
Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring.Expand
Designing Allosteric Inhibitors of Thrombin
Designing Allosteric Inhibitors of Thrombin By Preetpal Singh Sidhu A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia CommonwealthExpand
...
1
2
3
...